N/A Completed N=39 Randomized Single-blind Treatment

Effects Of Native Collagen Type 2 Treatment

Source: ClinicalTrials.gov NCT02237989 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2020

Primary outcomePrimary: the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking) — 3; 3 score on a scale

Summary

The aim of this study was to evaluate symptomatic efficacy of native collagen type 2 on joint pain and function and its effects on urinary biological markers related to cartilage degeneration in patients with knee osteoarthritis.

Outcome Measures

Outcome	Result	p-value
PRIMARY the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking)	3; 3	—
SECONDARY the Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score	52; 44	—
SECONDARY the Change From Baseline in 20 Meters Walking Time	18.84; 18	—
SECONDARY the Change From Baseline in Short Form 36 / Bodily Pain Subgroup	51; 52	—
SECONDARY the Change From Baseline in Coll2-1 Levels	130; 155.25	—

Eligibility Criteria

Inclusion Criteria:Patients aged 45-70 years with the diagnosis of primary knee OA according to the American College of Rheumatology (ACR) criteria, Kellgren Lawrence radiological stage II or III and knee pain - Exclusion Criteria:Patients with intraarticular injections or physical therapy within the last year, a previous lower extremity surgery, oral treatment with glucosamine chondroitin or other natural health products within the last month, serious concomitant systemic diseases, peripheral or central neurological disorder, hypersensitivity to paracetamol or se¬vere cardiac, renal, hepatic, hematologic disease -

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02237989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.